QIAGEN: Company Profile

 
   Single User - $250
   Site License (one location, 10 users) - $375
   Corporate License - $500


Loading...
Published Nov 9, 2015 | 39 Pages | Pub ID: KLI5734031

QIAGEN: Company Profile

QIAGEN is a leading global provider of sample and assay technologies that are used to transform biological materials into valuable molecular information. Sample technologies isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. QIAGEN provides tissue and liquid biopsy-based tests for personalized healthcare using companion diagnostics to guide the use of medicines for treatment of cancer and other diseases. The company markets tests in various markets covering a broad range of molecular biomarkers and running on PCR, multi-modal and next-generation sequencing platforms.

QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

QIAGEN: Company Profile examines the global healthcare company located in Venlo, The Netherlands, with operative and European headquarters located in Hilden, Germany, and further regional headquarters located in Maryland and Shanghai.

QIAGEN participates in many markets, including:
  • Personalized Healthcare
  • Infectious Disease Testing
  • Transplant Medicine and HAIs
  • HPV
  • Oncology
  • Companion Diagnostics
  • Liquid Biopsy/CTC
  • Sequencing
  • Exosomes
  • Sample Preparation
  • Point of Care
  • Forensics
The report notes agreements and partnerships that have added biomarkers and manufacturing capability to QIAGEN’s pipeline of diagnostics for personalized healthcare applications. Selected acquisitions, which help expand QIAGEN’s test menu, are also outlined.

QIAGEN has had an active 2015. The report discusses recent developments.

The information presented in this report is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.
ONE: EXECUTIVE SUMMARY
Overview
Methodology
TWO: COMPANY PROFILE
Recent Revenue History
Company Overview
Selected Markets
Personalized Healthcare
Infectious Disease Testing
Transplant Medicine and HAIs
HPV
Oncology
Companion Diagnostics
Liquid Biopsy/CTC
Instrumentation Base
Rotor-Gene Q – Clinical Diagnostics
Sequencing
Exosomes
Information Technology
Sample Preparation
Point of Care
Forensics
Collaborations
Various Partnerships/Agreements
Partnership with IntelligentMDx
Selected Acquisitions
Menu Expansion via Acquisition
QIAGEN Hannover (formerly AdnaGen GmbH)
Research and Development (R&D)
Recent QIAGEN Developments

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.